PURPOSE: Multiple myeloma (MM) is often associated with osteolytic bone disease and anemia, resulting in skeletal fragility and persistent fatigue, pain, and reduced quality of life. Exercise is considered safe and beneficial for this population. Our objectives were to evaluate the extent to which MM patients undergoing chemotherapy complied with exercise recommendations and to identify factors associated with noncompliance. METHODS: This retrospective study included 41 MM patients referred to a hospital-based rehabilitation program while undergoing chemotherapy. Variables collected at baseline (T1) and follow-up (T2) included: (a) demographics and medical history, (b) exercise levels (MET-hours/week), preferences and barriers, and (c) fatigue severity scores (0-10). Statistical analyses included logistic regression to identify factors associated with exercise noncompliance and t-tests and chi-squared tests to compare outcomes between the groups according to compliance. RESULTS: The mean age of the participants was 61 years; 73 % were male and 81 % had bone lesions. Overall exercise compliance at T2 was 71 %, with an observed increase in exercise levels (mean group difference: 6.5 MET-hours/week; p < 0.001) and decrease in fatigue severity scores (mean group difference -1.2; p = 0.003). Factors associated with exercise noncompliance included history of pathological fracture (odds ratio [OR] 4.7; p = 0.049), spinal cord compression (SCC) (OR 14.1; p = 0.023), and radiation (OR 28.0; p < 0.001). CONCLUSIONS: In this sample of MM patients, high compliance with exercise and associated improvements in fatigue were observed. However, participants with a history of pathological fracture, SCC, or radiation are at increased risk of noncompliance and may require additional supervision to improve exercise compliance.
PURPOSE:Multiple myeloma (MM) is often associated with osteolytic bone disease and anemia, resulting in skeletal fragility and persistent fatigue, pain, and reduced quality of life. Exercise is considered safe and beneficial for this population. Our objectives were to evaluate the extent to which MMpatients undergoing chemotherapy complied with exercise recommendations and to identify factors associated with noncompliance. METHODS: This retrospective study included 41 MMpatients referred to a hospital-based rehabilitation program while undergoing chemotherapy. Variables collected at baseline (T1) and follow-up (T2) included: (a) demographics and medical history, (b) exercise levels (MET-hours/week), preferences and barriers, and (c) fatigue severity scores (0-10). Statistical analyses included logistic regression to identify factors associated with exercise noncompliance and t-tests and chi-squared tests to compare outcomes between the groups according to compliance. RESULTS: The mean age of the participants was 61 years; 73 % were male and 81 % had bone lesions. Overall exercise compliance at T2 was 71 %, with an observed increase in exercise levels (mean group difference: 6.5 MET-hours/week; p < 0.001) and decrease in fatigue severity scores (mean group difference -1.2; p = 0.003). Factors associated with exercise noncompliance included history of pathological fracture (odds ratio [OR] 4.7; p = 0.049), spinal cord compression (SCC) (OR 14.1; p = 0.023), and radiation (OR 28.0; p < 0.001). CONCLUSIONS: In this sample of MMpatients, high compliance with exercise and associated improvements in fatigue were observed. However, participants with a history of pathological fracture, SCC, or radiation are at increased risk of noncompliance and may require additional supervision to improve exercise compliance.
Authors: Sundar Jagannath; Brian G M Durie; Jeffrey Wolf; Elber Camacho; David Irwin; Jose Lutzky; Marti McKinley; Eli Gabayan; Amitabha Mazumder; David Schenkein; John Crowley Journal: Br J Haematol Date: 2005-06 Impact factor: 6.998
Authors: Jennifer S Temel; William F Pirl; Christopher J Recklitis; Barbara Cashavelly; Thomas J Lynch Journal: J Thorac Oncol Date: 2006-06 Impact factor: 15.609
Authors: Nils Bergenthal; Andrea Will; Fiona Streckmann; Klaus-Dieter Wolkewitz; Ina Monsef; Andreas Engert; Thomas Elter; Nicole Skoetz Journal: Cochrane Database Syst Rev Date: 2014-11-11
Authors: Shiraz I Mishra; Roberta W Scherer; Claire Snyder; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: Elizabeth Ann Coleman; Julia A Goodwin; Robert Kennedy; Sharon K Coon; Kathy Richards; Carol Enderlin; Carol B Stewart; Paula McNatt; Kim Lockhart; Elias J Anaissie Journal: Oncol Nurs Forum Date: 2012-09 Impact factor: 2.172
Authors: Maria Gabriella Giganti; Ilaria Tresoldi; Roberto Sorge; Giovanni Melchiorri; Tamara Triossi; Laura Masuelli; Paolo Lido; Loredana Albonici; Calogero Foti; Andrea Modesti; Roberto Bei Journal: Oncol Lett Date: 2016-07-20 Impact factor: 2.967
Authors: M A Dalzell; N Smirnow; W Sateren; A Sintharaphone; M Ibrahim; L Mastroianni; L D Vales Zambrano; S O'Brien Journal: Curr Oncol Date: 2017-06-27 Impact factor: 3.677
Authors: Michael Mendes Wefelnberg; Timo Niels; Udo Holtick; Franziska Jundt; Christoph Scheid; Freerk T Baumann Journal: Support Care Cancer Date: 2022-10-03 Impact factor: 3.359